scholarly journals Differences between intravenous iron products: focus on treatment of iron deficiency in chronic heart failure patients

2019 ◽  
Vol 6 (2) ◽  
pp. 241-253 ◽  
Author(s):  
Alejandro Martin‐Malo ◽  
Gerrit Borchard ◽  
Beat Flühmann ◽  
Claudio Mori ◽  
Donald Silverberg ◽  
...  
Keyword(s):  
Heart Failure ◽  
Chronic Heart Failure ◽  
Iron Deficiency ◽  
Intravenous Iron ◽  
Heart Failure Patients

scholarly journals Anemia and Iron Deficiency in Heart Failure — Clinical Update

2017 ◽  
Vol 2 (4) ◽  
pp. 308-311 ◽  
Author(s):  
András Mester ◽  
Adriana Mitre ◽  
Erzsébet Lázár ◽  
István Benedek ◽  
Johanna Kéri ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Heart Failure ◽  
Chronic Heart Failure ◽  
Iron Deficiency ◽  
Oral Administration ◽  
Functional Capacity ◽  
Intravenous Iron ◽  
Hospitalization Rate ◽  
Heart Failure Patients

AbstractIron deficiency and anemia affect approximately half of the chronic heart failure patients and they are associated with increased hospitalization rate, lower functional capacity, lower quality of life, and higher mortality. The exact mechanism of iron deficiency in heart failure patients is still not fully understood. Current guidelines recommend ferritin as the most accurate serum biomarker for the diagnosis of iron deficiency. The use of erythropoiesis-stimulating agents is no longer recommended because of the lack of improvement on mortality or hospital readmission rate, and it was associated with a higher rate of thromboembolic events. Intravenous iron replacement therapy is safe and generally well tolerated, with fewer side effects compared to oral administration. Large randomized studies with ferric carboxymaltose demonstrated its effectiveness and superiority to oral administration, and it was associated with a decreased rate of hospitalization rate and worsening heart failure, and improvement of functional capacity and quality of life. Intravenous iron supplementation for chronic heart failure is strongly recommended by European guidelines. Further studies are needed for a better knowledge of this complex pathology and determination of the long-term safety and effectiveness of iron administration in chronic heart failure patients. .

scholarly journals Role of comorbidities in heart failure prognosis Part I: Anaemia, iron deficiency, diabetes, atrial fibrillation

2020 ◽  
Vol 27 (2_suppl) ◽  
pp. 27-34
Author(s):  
Stefania Paolillo ◽  
Angela B Scardovi ◽  
Jeness Campodonico
Keyword(s):  
Diabetes Mellitus ◽  
Heart Failure ◽  
Atrial Fibrillation ◽  
Chronic Heart Failure ◽  
Iron Deficiency ◽  
Prognostic Impact ◽  
Heart Failure Patients ◽  
Cardiovascular Comorbidities ◽  
Long Term Prognosis

Cardiovascular and non-cardiovascular comorbidities are frequently observed in heart failure patients, complicating the therapeutic management and leading to poor prognosis. The prompt recognition of associated comorbid conditions is of great importance to optimize the clinical management, the follow-up, and the treatment of patients affected by chronic heart failure. Anaemia and iron deficiency are commonly reported in all heart failure forms, have a multifactorial aetiology and are responsible for reduced exercise tolerance, impaired quality of life, and poor long-term prognosis. Diabetes mellitus is highly prevalent in heart failure and a poor glycaemic control is associated with worst outcome. Two specific heart failure forms are usually observed in diabetic patients: an ischaemic cardiomyopathy or a typical diabetic cardiomyopathy. The implementation of use of sodium-glucose cotransporter-2 inhibitors will much improve in the near future the long-term prognosis of patients affected by heart failure and diabetes. Among cardiovascular comorbidities, atrial fibrillation is the most common arrhythmic disease of heart failure patients and it is still not clear whether its presence should be considered as a prognostic indicator or as a marker of advanced disease. The aim of the present review was to explore the clinical and prognostic impact of anaemia and iron deficiency, diabetes mellitus, and atrial fibrillation in patients affected by chronic heart failure.

scholarly journals Effect of Intravenous Iron Sucrose on Exercise Tolerance in Anemic and Nonanemic Patients With Symptomatic Chronic Heart Failure and Iron Deficiency

2008 ◽  
Vol 51 (2) ◽  
pp. 103-112 ◽  
Author(s):  
Darlington O. Okonko ◽  
Agnieszka Grzeslo ◽  
Tomasz Witkowski ◽  
Amit K.J. Mandal ◽  
Robert M. Slater ◽  
...  
Keyword(s):  
Heart Failure ◽  
Chronic Heart Failure ◽  
Iron Deficiency ◽  
Exercise Tolerance ◽  
Intravenous Iron ◽  
Iron Sucrose

scholarly journals Iron deficiency status irrespectively of anaemia: a predictor of unfavorable outcome in chronic heart failure patients

2013 ◽  
Vol 34 (suppl 1) ◽  
pp. P1510-P1510
Author(s):  
I. Rangel ◽  
A. Goncalves ◽  
C. Sousa ◽  
S. Leite ◽  
M. Campelo ◽  
...  
Keyword(s):  
Heart Failure ◽  
Chronic Heart Failure ◽  
Iron Deficiency ◽  
Unfavorable Outcome ◽  
Heart Failure Patients

scholarly journals Correction of Iron Deficiency in Hospitalized Heart Failure Patients Does Not Improve Patient Outcomes

Blood ◽  
2019 ◽  
Vol 134 (Supplement_1) ◽  
pp. 4812-4812
Author(s):  
Ronak Mistry ◽  
Andrew Kohut ◽  
Patricia Locantore-Ford
Keyword(s):  
Quality Of Life ◽  
Heart Failure ◽  
Chronic Heart Failure ◽  
Iron Deficiency ◽  
Functional Outcomes ◽  
Chronic Medical Condition ◽  
Large Trial ◽  
Heart Failure Patients ◽  
Iron Deficient

Background: Heart failure (HF) is a chronic medical condition that affects approximately 1-2% of the world's population and greater than 10% of those age 65 and older. Among patients with HF, iron deficiency (ID), defined as ferritin <100 ng/ml or transferrin saturation (TSat) <20% with ferritin 100-300 ng/ml, has an estimated prevalence of 30-50%, often without concomitant anemia. Thus, ID in HF is often underdiagnosed unless actively sought after. ID in HF has been shown to be an independent contributor of increased mortality, hospitalization and early readmission compared to HF patients without ID or HF patients with anemia without ID. A large trial, namely IRONOUT, illustrated the superiority of intravenous iron (IVFe) over oral iron supplements for HF patients who were identified as iron deficient. The FAIR-HF and CONFIRM-HF trials showed improved functional outcomes and quality of life in HF patients treated with IVFe and that these benefits were conferred even 1 year after treatment. However, these trials focus on iron store correction in patients with chronic heart failure patients. Little data are available regarding the correction of ID in patients who are admitted to hospitals for HF exacerbations. Methods: We performed a retrospective analysis of hospital records of patients admitted with HF as a primary or secondary diagnosis to a city-based large academic teaching health system between April 1, 2014 and April 1, 2017. Thereafter, we identified those patients who had sufficient iron studies (hemoglobin, iron, ferritin, transferrin, TSat) during their hospitalization to diagnose ID, as per the criteria above. Patients with ID were then stratified into those that did and did not receive IVFe. Patient charts were evaluated to two primary endpoints, namely one-year readmissions for HF and patient mortality. Results: In total, 390 patients had sufficient iron studies performed to assess ID status, of which 279 met criteria for ID (71.5%). Eighty-four of the 279 patients received IVFe. Amongst patients that received IVFe, 38 patients were readmitted for HF (45.2%) and 6 patient deaths occurred within 1 year (7.14%). Amongst the remaining 195 patients who did not receive IVFe, 93 were readmitted for HF (47.69%) and 15 patient deaths occurred within 1 year (7.69%). Conclusion: These data suggest that despite clinical benefit in patient functional outcomes and overall quality of life in chronic heart failure patients treated with IVFe, treatment of ID in acute HF patients does not result in a reduction in admissions for HF or improvements in patient mortality. Disclosures No relevant conflicts of interest to declare.

Sign in / Sign up

Export Citation Format

Share Document